Biostatistics Article 3: N-of-1 Trials & Their Use in Neuromodulation with Prof. Konstantin Slavin

In this episode, Prof. Konstantin Slavin reads aloud an article by Garston Liang, Quentin F. Gronau, and Alexander Thorpe which addresses the use of N-of-1 trials in neuromodulation and personalized medicine. N-of-1 trials are a powerful method for investigating treatment effects on an individual basis, making them ideal for patients with stable symptoms and chronic disorders.Key points covered include:- N-of-1 Trial Design: Involves repeated cycles of treatment and placebo, with the patient serving as their own control.- Personalization: Tailors treatment decisions to individual outcomes, offering a high level of evidence for treatment efficacy.- Double-Blinding: Ensures both patient and clinician are unaware of the treatment phase to maintain objectivity.- Crossover Design: Alternates between treatment and placebo phases, often randomized to prevent time-related biases.- Wash-In/Out Periods: Important for avoiding carry-over effects, especially in pharmaceutical interventions.The article also highlights the statistical considerations for analyzing N-of-1 trials, emphasizing the importance of proper design and analysis to ensure valid conclusions. Tune in to learn how N-of-1 trials can enhance personalized treatment strategies in neuromodulation and beyond. Resources: Biostatistics articles on the INS website N-of-1 Trials & Their Use in Neuromodulation